We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · April 19, 2021

Post-Approval Comparative Safety Study of Tofacitinib and Biological DMARDs

ACR Open Rheumatology


Additional Info

ACR Open Rheumatology
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results From a United States-Based Rheumatoid Arthritis Registry
ACR Open Rheumatol 2021 Mar 01;3(3)173-184, JM Kremer, CO Bingham, LC Cappelli, JD Greenberg, AM Madsen, J Geier, JL Rivas, AM Onofrei, CJ Barr, DA Pappas, HJ Litman, KJ Dandreo, AB Shapiro, CA Connell, A Kavanaugh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading